Health-related quality of life 1–3 years post-myocardial infarction: its impact on prognosis
Stuart Pocock(London School of Hygiene & Tropical Medicine), Richard Grieve(MRC Clinical Trials Unit at UCL), Mauricio G. Cohen(Santa Ana College), Christopher B. Granger(Clinical Research Institute), Satoshi Yasuda(Tohoku University), Karolina Andersson Sundell(AstraZeneca (Brazil)), Jiyan Chen(Guangdong Provincial Center for Disease Control and Prevention), Katarina Hedman(AstraZeneca (Brazil)), David Brieger(The University of Sydney), Shaun G. Goodman(University of Toronto), Dirk Westermann(University Medical Center Freiburg), Tabassome Simon(Sorbonne Université), José Carlos Nicolau(Hospital São Paulo), Carl Mellström(AstraZeneca (Brazil)), Ruth Owen(Spanish National Centre for Cardiovascular Research)
Cited by 68
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
|New England Journal of Medicine|2011|6.4k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k